Bortezomib Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
IB/0029 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
25/03/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0027 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
20/12/2021 
SmPC 
life of the finished product - As packaged for sale 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
(supported by real time data) 
IA/0028 
A.7 - Administrative change - Deletion of 
13/12/2021 
manufacturing sites 
Annex II and 
PL 
X/0023 
Annex I_2.(c) Change or addition of a new 
20/05/2021 
23/07/2021 
SmPC, Annex 
strength/potency 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
II, Labelling 
and PL 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
10/12/2020 
18/02/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02004 
bortezomib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/424/202004. 
IAIN/0026/G 
This was an application for a group of variations. 
22/12/2020 
23/07/2021 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0024 
C.I.11.z - Introduction of, or change(s) to, the 
07/05/2020 
18/02/2021 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
R/0022 
Renewal of the marketing authorisation. 
27/02/2020 
04/05/2020 
SmPC, Annex 
II, Labelling 
and PL 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
01904 
bortezomib 
IB/0020 
B.II.b.4.z - Change in the batch size (including batch 
10/07/2019 
n/a 
size ranges) of the finished product - Other variation 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/03/2019 
03/04/2020 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0019 
B.II.b.2.c.1 - Change to importer, batch release 
05/03/2019 
03/04/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0017 
Transfer of Marketing Authorisation 
11/01/2019 
25/02/2019 
SmPC, 
Labelling and 
PL 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
13/12/2018 
20/02/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01804 
bortezomib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/424/201804. 
II/0014 
B.I.a.1.b - Change in the manufacturer of AS or of a 
17/01/2019 
n/a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0016/G 
This was an application for a group of variations. 
16/10/2018 
20/02/2019 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
X/0008 
Annex I_2.(c) Change or addition of a new 
22/03/2018 
28/05/2018 
SmPC, Annex 
strength/potency 
II, Labelling 
and PL 
IAIN/0013 
B.II.b.2.c.1 - Change to importer, batch release 
17/04/2018 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0012 
B.II.b.4.d - Change in the batch size (including batch 
18/01/2018 
n/a 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
30/11/2017 
n/a 
PRAC Recommendation - maintenance 
01704 
bortezomib 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/07/2017 
28/05/2018 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IB/0009/G 
This was an application for a group of variations. 
29/05/2017 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
IA/0007 
A.5.b - Administrative change - Change in the name 
14/09/2016 
n/a 
and/or address of a manufacturer/importer of the 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0006/G 
This was an application for a group of variations. 
06/04/2016 
02/05/2016 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0005 
B.II.e.3.b - Change in test procedure for the 
29/03/2016 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
II/0001 
B.II.b.4.d - Change in the batch size (including batch 
19/11/2015 
n/a 
size ranges) of the finished product - The change 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
IAIN/0003/G 
This was an application for a group of variations. 
21/08/2015 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0002 
B.II.b.5.z - Change to in-process tests or limits 
18/08/2015 
n/a 
applied during the manufacture of the finished 
product - Other variation 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
